Table 1.
Characteristics of included studies.
| References | Tracer | Outcome | Subjects | Age | Male (%) | Duration (y) | UPDRS-III | MMSE | MoCA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PD | PDCI | PDD | HCs | DLB | PSP | AD | MSA-P | MSA-C | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | ||||
| Kepe et al. (20) | [18F] FDDNP | DVR | 8 | N/A | N/A | 5 | N/A | 15 | N/A | N/A | N/A | 57.90 ± 10.00 | 50.00 | 2.40 ± 1.10 | 13.10 ± 6.70 | 28.50 ± 2.30 | Un |
| Cho et al. (15) | [18F] AV-1451 | SUVR | 14 | N/A | N/A | 15 | N/A | 15 | N/A | N/A | N/A | 67.90 ± 5.40 | 53.33 | 5.50 ± 3.50 | 26.90 ± 11.20 | 26.90 ± 1.90 | Un |
| Coakeley et al. (16) | [18F] AV-1451 | SUVR | 6 | N/A | N/A | 10 | N/A | 6 | N/A | N/A | N/A | 63.67 ± 9.61 | 50.00 | 5.50 ± 2.43 | 26.30 ± 3.01 | Un | 28.30 ± 0.72 |
| Buongiorno et al. (8) | [18F] FDDNP | DVR | 16 | N/A | 8 | 8 | N/A | N/A | N/A | N/A | N/A | 73.00 ± 4.25 | 60.00 | Un | 23.00 ± 8.00 | 29.00 ± 1.00 | Un |
| Gomperts et al. (18) | [18F] AV-1451 | SUVR | 9 | 8 | N/A | 29 | 7 | N/A | N/A | N/A | N/A | 67.00 ± 3.00 | 88.89 | Un | 23.30 ± 12.80 | 29.10 ± 0.40 | Un |
| Schonhaut et al. (25) | [18F] AV-1451 | SUVR | 26 | N/A | N/A | 46 | N/A | 33 | N/A | N/A | N/A | 67.10 ± 5.40 | 53.85 | Un | 26.10 ± 11.40 | Un | Un |
| Hansen et al. (19) | [18F] AV-1451 | SUVR | 17 | 9 | N/A | 23 | N/A | N/A | N/A | N/A | N/A | 67.60 ± 6.30 | 76.47 | 4.50 ± 3.20 | 19.20 ± 8.40 | 28.90 ± 1.30 | 27.50 ± 1.70 |
| Coakeley et al. (17) | [18F] AV-1451 | SUVR | 6 | N/A | N/A | 10 | N/A | 6 | N/A | N/A | N/A | 63.67 ± 9.61 | 50.00 | 5.50 ± 2.43 | 26.30 ± 3.01 | Un | 28.30 ± 0.72 |
| Lee et al. (21) | [18F] AV-1451 | SUVR | 12 | 22 | N/A | 25 | 18 | N/A | 25 | N/A | N/A | 67.60 ± 6.30 | 58.33 | 3.51 ± 2.91 | 25.80 ± 11.30 | 27.20 ± 1.90 | Un |
| Ossenkoppele et al. (27) | [18F] AV-1451 | SUVR | 23 | 70 | N/A | 160 | 24 | 40 | 83 | N/A | N/A | 67.30 ± 5.80 | 65.20 | Un | Un | 27.60 ± 1.90 | Un |
| Schönecker et al. (24) | 18F-THK-5351 | SUVR | 6 | N/A | N/A | N/A | N/A | 13 | N/A | 9 | 6 | 65.70 ± 8.10 | 33.33 | Un | Un | 29.40 ± 1.30 | Un |
| Smith et al. (26) | [18F] AV-1451 | SUVR | 11 | N/A | 18 | N/A | 6 | N/A | N/A | N/A | N/A | 67.00 ± 5.50 | 72.73 | Un | 11.00 ± 8.00 | 28.00 ± 2.00 | Un |
| Brendel et al. (14) | 18F-PI-2620 | SUVR | 6 | N/A | N/A | 10 | N/A | 60 | 10 | N/A | N/A | 60.00 ± 10.00 | 66.67 | 1.42 ± 0.75 | 22.50 ± 6.30 | Un | 27.0 ± 4.0 |
| Li et al. (22) | [18F] AV-1451 | SUVR | 8 | N/A | N/A | 10 | N/A | 7 | 4 | N/A | N/A | 66.40 ± 5.70 | 25.00 | 8.10 ± 6.60 | 18.10 ± 14.60 | 27.40 ± 4.30 | Un |
| Li et al. (23) | 18F-APN-1607 | SUVR | 10 | N/A | N/A | 13 | N/A | 20 | N/A | 7 | N/A | 59.40 ± 16.30 | 60.00 | 2.49 ± 1.44 | 38.90 ± 17.10 | 25.40 ± 4.30 | Un |
PD, Parkinson's disease; PDCI, Parkinson's disease with cognitive impairment; PDD, Parkinson's disease dementia; HCs, healthy controls; DLB, dementia with Lewy bodies; PSP, progressive supranuclear palsy; AD, Alzheimer's disease; MSA-P, multiple system atrophy–parkinsonian type; UPDRS, Unified Parkinson's Disease Rating Scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; SUVR, standard uptake value ratio; DVR, distribution volume ratios; SD, standard deviation.